[HTML][HTML] Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this …
D Singh, V Balaguer, C Astbury, U Wählby-Hamrén… - Respiratory …, 2020 - Springer
Background Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β 2−
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …
[PDF][PDF] Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this …
D Singh, V Balaguer, C Astbury, U Wählby-Hamrén… - 2020 - scholar.archive.org
Abstract Background: Navafenterol (AZD8871) is a dual-pharmacology muscarinic
antagonist β2− agonist (MABA) molecule in development for the treatment of chronic …
antagonist β2− agonist (MABA) molecule in development for the treatment of chronic …
[PDF][PDF] Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this …
D Singh, V Balaguer, C Astbury, U Wählby-Hamrén… - 2020 - academia.edu
Abstract Background: Navafenterol (AZD8871) is a dual-pharmacology muscarinic
antagonist β2− agonist (MABA) molecule in development for the treatment of chronic …
antagonist β2− agonist (MABA) molecule in development for the treatment of chronic …
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel …
D Singh, V Balaguer, C Astbury… - Respiratory …, 2020 - europepmc.org
Background Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β 2-
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel …
D Singh, V Balaguer, C Astbury… - Respiratory …, 2020 - search.proquest.com
Background Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β 2−
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …
[HTML][HTML] Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this …
D Singh, V Balaguer, C Astbury… - Respiratory …, 2020 - ncbi.nlm.nih.gov
Background Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β 2−
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …
[HTML][HTML] Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this …
D Singh, V Balaguer, C Astbury… - Respiratory …, 2020 - respiratory-research.biomedcentral …
Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β2− agonist (MABA)
molecule in development for the treatment of chronic obstructive pulmonary disease …
molecule in development for the treatment of chronic obstructive pulmonary disease …
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel …
D Singh, V Balaguer, C Astbury… - Respiratory …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β 2-
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel …
D Singh, V Balaguer, C Astbury… - Respiratory …, 2020 - search.ebscohost.com
Abstract < bold> Background: </bold> Navafenterol (AZD8871) is a dual-
pharmacology muscarinic antagonist β2-agonist (MABA) molecule in development for the …
pharmacology muscarinic antagonist β2-agonist (MABA) molecule in development for the …
[PDF][PDF] Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this …
D Singh, V Balaguer, C Astbury… - 2020 - respiratory-research.biomedcentral …
Abstract Background: Navafenterol (AZD8871) is a dual-pharmacology muscarinic
antagonist β2− agonist (MABA) molecule in development for the treatment of chronic …
antagonist β2− agonist (MABA) molecule in development for the treatment of chronic …